BioSpace News Archive

PhenomeX Inc., the functional cell biology company, announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery.

Diligent Pharma Inc. announced today, the closing of an $8.27 Million Series A financing round led by FCA Venture Partners. Additional investors include PJC, and GenHenn Capital along with private investors who have held executive leadership roles in the pharmaceutical industry.

Kinaset Therapeutics today announced an upcoming presentation at the ATS 2023 Respiratory Innovation Summit being held in Washington D.C. May 19-20, 2023.

CEL-SCI Corporation announced that the latest results from its pivotal Phase 3 study of Multikine were presented at the ESTRO 2023 Congress in Vienna, Austria in a poster presentation titled “Histopathology population confirms Multikine* [Leukocyte Interleukin Injection ] treatment outcome in naïve locally advanced primary head & neck squamous cell carcinoma SCCHN)” during the Head & Neck Cancer Session on Saturday, May 13, 2023.

Therapeutic Solutions International (TSOI) spin-off Res Nova Bio announced today a collaboration with Cure Stat Rx, a premiere compounding Pharmacy in the manufacture of initiate doses of FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.

Evotec SE today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023.

Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today provides a corporate update and announces its first quarter 2023 financial results.

Invirsa’s first clinical trial, a Phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa’s topically administered eyedrop formulation of INV-102, has completed enrollment.

RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life changing medicines, is pleased to announce that is has joined BioNTX, the bioscience and healthcare innovation trade organization serving North Texas.

CathVision today announced an extensive slate of educational opportunities and scientific sessions at this year’s Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics.